Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
22.8%
0%
22.8%
6 Months
17.42%
0%
17.42%
1 Year
10.89%
0%
10.89%
2 Years
-53.05%
0%
-53.05%
3 Years
-39.86%
0%
-39.86%
4 Years
-18.57%
0%
-18.57%
5 Years
-35.29%
0%
-35.29%
Crossject SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-9.83%
EBIT to Interest (avg)
-12.31
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-3.10
Sales to Capital Employed (avg)
0.04
Tax Ratio
18.09%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-55.95
EV to EBIT
-9.80
EV to EBITDA
-15.95
EV to Capital Employed
13.57
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-138.48%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
0.10
1.00
-90.00%
Operating Profit (PBDIT) excl Other Income
-10.10
-8.00
-26.25%
Interest
0.50
0.30
66.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-8.60
-11.20
23.21%
Operating Profit Margin (Excl OI)
-100,448.30%
-13,865.80%
-8,658.25%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is -90.00% vs 11.11% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is 23.21% vs -3.70% in Dec 2022
About Crossject SA 
Crossject SA
Pharmaceuticals & Biotechnology
Crossject SA is a France-based company that designs and develops medical injection systems. The Company specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The Company's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject’s first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The Company has industrial partnerships with Hirtenberger and Recipharm.
Company Coordinates 
Company Details
Parc Mazen-Sully, 6 Rue Pauline Kergomard DIJON None : 21000
Registrar Details






